Navigation Links
MIT scientist launches special nanoscience symposia at ACS National Meeting
Date:3/17/2009

SALT LAKE CITY, March 22, 2009 Angela M. Belcher, Ph.D., a noted scientist from Massachusetts Institute of Technology (MIT), will deliver the Keynote Address in Nanoscience here today at the American Chemical Society's 237th National Meeting.

Her presentation will launch more than 135 symposia on various aspects of nanoscience to be held over the next five days. The symposia are in the areas of General Nanoscience, Green Nanoscience, Safety Nanoscience and Materials/Applications.

Belcher's research, NANO 1, will be presented at 5:00 p.m. (Mountain Time) on March 22, at the Salt Palace Convention Center, Hall 2.

Angela M. Belcher, Ph.D, is Germeshausen Professor of Materials Science and Engineering and Biological Engineering at Massachusetts Institute of Technology, Cambridge, Mass.

NANO 1 Presentation Title: "Nanoscience. From Nature and Back Again: Giving New Life to Materials for Energy" (No abstract available.)

Among the numerous nanotechnology symposia at the meeting is a special Presidential Symposium, (*PRES 1150-1188) "Naturally Nano," to be held Tuesday, March 24, 8:30 a.m. to 6 p.m. at the Marriott City Center, Capitol A. ACS President Thomas H. Lane, Ph.D., will deliver the concluding remarks at this symposium.

*NOTE TO REPORTERS: "PRES 1150-1188" refers to the corresponding abstract numbers in the Presidential symposium of the ACS national meeting program. ALL PRESENTATIONS IN THIS SYMPOSIUM ARE EMBARGOED FOR 8:30 a.m., Mountain Time.

Following are the speakers for the session and their topics:

  • Geoffery A. Ozin, Ph.D., Materials Chemistry Research Group, Department of Chemistry, University of Toronto, Lash Miller Chemical Laboratories, Toronto, Canada. Topic: P-Ink and Elast-Ink lab to Market. (CHED 1150, 8:40 a.m.)

  • Howard Fairbrother, Ph.D., Department of Chemistry, Johns Hopkins University, Baltimore, Md. Topic: Influence of Surface Chemistry on
    '/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... 2014 Giving patients adrenaline after they suffer a cardiac ... prospects of surviving long-term, according to new research conducted ... patients who have a cardiac arrest get adrenaline, which ... for decades," said Dr. Steve Lin, an emergency physician ... advances in medical treatment, long-term survival rates of patients ...
(Date:4/17/2014)... LSTM have called for more research to be ... children in sub-Saharan Africa. In a paper in ... Russell Stothard, working with colleagues in the department ... University, in Cleveland Ohio, University of Cambridge and ... into the joint burden of HIV/AIDS and schistosomiasis ...
(Date:4/16/2014)... Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that final ... solid tumors, including long-term patient follow-up, have been published ... 232). The data demonstrate robust antibody and T cell ... very advanced cancers and suggest that CDX-1401 may predispose ...
(Date:4/16/2014)... it is well known that fertility treatments are the ... multiples are at elevated risk of premature birth, these ... Fertility and Sterility . The article identifies ... the odds of multiple births and prematurity, including expanding ...
(Date:4/15/2014)... , , CHAMPAIGN, Ill. Scientists have solved a decades-old medical mystery ... way to fight invasive fungal infections, which kill about 1.5 million ... of action of amphotericin, an antifungal drug that has been in ... nearly as toxic to human cells as it is to the ...
Breaking Medicine News(10 mins):Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3
... BMR, TORONTO, Dec. 12 /PRNewswire-FirstCall/ - Bradmer ... and,commercialization of cancer therapies, today announced that Keith ... to join the Company,s Scientific,Advisory Board. Dr. Black ... America, having performed more than 5,000 operations for ...
... Patient organizations support extending MSP and using savings ... American Kidney Fund and DaVita Patient Citizens submit ... WASHINGTON, Dec. 12 -Kidney Care Partners --,a ... manufacturers working together to improve quality of care ...
... Asia, Africa may not apply to patients in the ... Disappointing the hopes of researchers, new trials using a ... little or no benefit from the drugs. , "It ... lecturer in infectious diseases at the University of Malawi ...
... movies and TV shows make light of womens so-called ... or, conversely, to menopause. In fact, mood disorders are ... studies have found women are 1.5 to 3 times ... are men. , In a newly published study, ...
... Scient,x USA, an innovative,leader in the development and marketing ... today that Bryce T. IntVeld has,joined the Company as ... provide leadership and oversee the establishment and expansion,of sales ... delighted to have Bryce as a member of our ...
... WASHINGTON, Dec. 12 The Long Term Care,Pharmacy ... policy voice,for pharmacies which specifically serve nursing home ... its membership to include LTC pharmacy,companies that serve ... living in 47 states., "LTCPA represents highly ...
Cached Medicine News:Health News:Bradmer announces additions to Scientific Advisory Board 2Health News:Bradmer announces additions to Scientific Advisory Board 3Health News:Kidney Patient Organizations, Kidney Community Come Out in Support of Medicare Secondary Payer (MSP) Extension 2Health News:Kidney Patient Organizations, Kidney Community Come Out in Support of Medicare Secondary Payer (MSP) Extension 3Health News:Steroid Fails to Ease Meningitis in Trials 2Health News:Steroid Fails to Ease Meningitis in Trials 3Health News:Experts call for better research into link between women's hormones and mood disorders 2Health News:Scient'x USA Strengthens Leadership Team With Appointment of Bryce IntVeld as Vice President of Sales 2Health News:Long Term Care Pharmacy Alliance Expands Membership; Members Now Serve Most of the Nation's Nursing Home Residents 2
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Inc.,(Nasdaq: MEDX ) today announced interim ... an investigational oncology immunotherapy, as monotherapy or ... castration,resistant prostate cancer (mCRPC). Data presented showed ... was clinically active and,generally well-tolerated. Preliminary evidence ...
... and REGENSBURG, Germany, June 2 "A ... in recurrent or refractory anaplastic,astrocytoma suggests a ... commented Prof. Ulrich Bogdahn, Neuro-Oncologist and Coordinating,Investigator ... with AP,12009 in recurrent or refractory high-grade ...
Cached Medicine Technology:Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting 2Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting 3Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting 4Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 2Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 3Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 4
The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan...
The First Aid for the Surgery Clerkship is designed to prepare for the surgery clerkship examination and provides clinical diagnosis and treatment of many of the problems seen by surgeons....
CURRENT Consult: Surgery brings you authoritative clinical answers on more than 360 surgically treated disorders in the most efficient format, perfectly devised for the busy physician....
... enable all those involved with healthcare decisions ... very latest evidence in their field of ... each year as the volume of evidence ... delivering the best single source available for ...
Medicine Products: